Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers

[1]  G. Schreiber,et al.  The molecular basis for functional plasticity in type I interferon signaling. , 2015, Trends in immunology.

[2]  Jongtae Lee,et al.  Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model , 2013, Journal of Translational Medicine.

[3]  P. López-Saura,et al.  Development of a new formulation of interferons (HEBERPAG) for BCC treatment , 2013 .

[4]  E. García‐Iglesias,et al.  Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial , 2012, BMC Pharmacology and Toxicology.

[5]  P. López-Saura,et al.  Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study , 2010, BMC pharmacology.

[6]  Diane R Mould,et al.  Population Pharmacokinetic‐Pharmacodynamic Modeling of Biological Agents: When Modeling Meets Reality , 2010, Journal of clinical pharmacology.

[7]  P. López-Saura,et al.  Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study , 2009, BMC Cancer.

[8]  Bryan R. G. Williams,et al.  Interferon-inducible antiviral effectors , 2008, Nature Reviews Immunology.

[9]  R. Bruno,et al.  Pharmacodynamics of peginterferon alfa‐2a and peginterferon alfa‐2b in interferon‐naïve patients with chronic hepatitis C: a randomized, controlled study , 2007 .

[10]  L. Rostaing,et al.  Pegylation of IFN-α and Antiviral Activity , 2006 .

[11]  Takuma Tsukahara,et al.  Differential gene induction by type I and type II interferons and their combination. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[12]  C. Biddle.  The neurobiology of the human febrile response. , 2006, AANA journal.

[13]  D. Shukla,et al.  T2 weighted MRI in assessment of volume changes during radiotherapy of high grade gliomas. , 2005, Journal of cancer research and therapeutics.

[14]  Xue-Jun Sun,et al.  Fever of recombinant human interferon-alpha is mediated by opioid domain interaction with opioid receptor inducing prostaglandin E2 , 2004, Journal of Neuroimmunology.

[15]  J. Panetta,et al.  Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer , 2004, Cancer Chemotherapy and Pharmacology.

[16]  P. Ferenci.  PEGINTERFERON ALFA‐2A (40KD) (PEGASYS®) FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C , 2003, International journal of clinical practice.

[17]  R. Bruno,et al.  Viral Dynamics and Pharmacokinetics of Peginterferon Alpha-2A and Peginterferon Alpha-2B in Naive Patients with Chronic Hepatitis C: A Randomized, Controlled Study , 2003, Antiviral therapy.

[18]  Donald E. Mager,et al.  Receptor-Mediated Pharmacokinetic/Pharmacodynamic Model of Interferon-β 1a in Humans , 2002, Pharmaceutical Research.

[19]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[20]  R. Motzer,et al.  Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Saura,et al.  Antibodies against IFN γ-Binding Proteins Recognize a Member of IFN α R Complex , 2001 .

[22]  Alain Munafo,et al.  Pharmacokinetics and Pharmacodynamics of IFN-β1a in Healthy Volunteers , 2000 .

[23]  T. Taniguchi,et al.  Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. , 2000, Science.

[24]  G. Houin,et al.  A pharmacokinetic model for alpha interferon administered subcutaneously. , 1999, British journal of clinical pharmacology.

[25]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[26]  W J Jusko,et al.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. , 1998, British journal of clinical pharmacology.

[27]  Michele C. Clark,et al.  The University of Texas Medical Branch at Galveston , 1997 .

[28]  J. Romijn,et al.  Effects of interferon‐alpha (IFN‐α) administration on leucocytes in healthy humans , 1997, Clinical and experimental immunology.

[29]  D. Mould,et al.  Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa‐2a and a polyethylene glycol‐modified derivative in healthy subjects , 1996, Clinical pharmacology and therapeutics.

[30]  J. Zhi,et al.  Influence of Human Serum Albumin Content in Formulations on the Bioequivalency of Interferon Alfa‐2a Given by Subcutaneous Injection in Healthy Male Volunteers , 1995, Journal of clinical pharmacology.

[31]  N. Niederle,et al.  Induction of 2'-5' oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia. , 1992, Molecular biotherapy.

[32]  D. Estell,et al.  Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons , 1984, Journal of virology.

[33]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[34]  D. Fuchs,et al.  Neopterin, a prognostic marker in human malignancies. , 2010, Cancer letters.

[35]  F. Garrido,et al.  MHC class I antigens and immune surveillance in transformed cells. , 2007, International review of cytology.

[36]  L. Rostaing,et al.  Pegylation of IFN-alpha and antiviral activity. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[37]  P. López-Saura,et al.  Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. , 2004, Drugs in R&D.

[38]  P. López-Saura,et al.  Bioequivalence of Two Recombinant Interferon α-2b Liquid Formulations in Healthy Male Volunteers , 2004 .

[39]  P. Saura,et al.  Antibodies against IFN gamma-binding proteins recognize a member of IFN alpha R complex. , 2001, Biochemical and biophysical research communications.

[40]  A. Munafo,et al.  Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[41]  P. López-Saura,et al.  Comparative Pharmacokinetics and Pharmacodynamics of Two Recombinant Human Interferon Alpha-2b Formulations Administered Intramuscularly in Healthy Male Volunteers , 2000 .

[42]  T. MacVittie,et al.  Therapeutic evaluation of interleukin-1 for stimulation of hematopoiesis in primates after autologous bone marrow transplantation , 1992, Biotherapy.

[43]  S. Nagata.  [Human alpha, beta and gamma interferons]. , 1982, Nihon rinsho. Japanese journal of clinical medicine.